Seminars in Oncology
Volume 30, Issue 5 , Pages 616-634 , October 2003

Advances in imaging in the postoperative patient with a rising prostate-specific antigen level

  • Hedvig Hricak

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to Hedvig Hricak, MD, PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, C278, New York, NY 10021, USA
    • ,
  • Heiko Schöder

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Darko Pucar

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Eric Lis

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Steven C Eberhardt

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Chinyere N Onyebuchi

      Affiliations

    • Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Howard I Scher

      Affiliations

    • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

References 

  1. Jemal A, Thomas A, Murray T, et al.  Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23–47
  2. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–1507
  3. D’Amico AV, Whittington R, Malkowicz SB, et al.  The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol. 1998;160:2096–2101
  4. Partin AW, Pearson JD, Landis PK, et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649–659
  5. Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy (Defining local versus systemic failure). Semin Urol Oncol. 1999;17:130–134
  6. Laufer M, Pound CR, Carducci MA, et al.  Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology. 2000;55:309–315
  7. Catalona WJ, Smith DS. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837–1842
  8. Zincke H, Oesterling JE, Blute ML, et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850–1857
  9. Trapasso JG, deKernion JB, Smith RB, et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. 1994;Urol 152:1821–1825
  10. Pound CR, Partin AW, Eisenberger MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  11. Goldenberg SL, Carter M, Dashefsky S, et al.  Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol. 1992;147:1307–1309
  12. Lightner DJ, Lange PH, Reddy PK, et al.  Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 1990;144:921–926
  13. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer (Intermediate-term results). J Urol. 1998;160:2428–2434
  14. Foster LS, Jajodia P, Fournier G, et al.  The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 1993;149:1024–1028
  15. Morton RA, Steiner MS, Walsh PC. Cancer control following anatomical radical prostatectomy (An interim report). J Urol. 1991;145:1197–1200
  16. Nash PA, Bruce JE, Indudhara R, et al.  Transrectal ultrasound guided prostatic nerve lockade eases systematic needle biopsy of the prostate. J Urol. 1996;155:607–609
  17. Parra RO, Wolf RM, Huben RP. The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation. J Urol. 1990;144:707–709
  18. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen (Update 1994). J Urol. 1994;152:1358–1368
  19. Critz FA, Levinson AK, Williams WH, et al.  Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy. J Urol. 1999;161:1199–1203
  20. Oyen RH, Van Poppel HP, Ameye FE, et al.  Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy (Prospective study of 285 patients). Radiology. 1994;190:315–322
  21. Flocks RH, Culp D, Porto R. Lymphatic spread from prostate cancer. J Urol. 1959;81:194–196
  22. Spencer JA, Golding SJ. Patterns of lymphatic metastases at recurrence of prostate cancer (CT findings). Clin Radiol. 1994;49:404–407
  23. Taoka T, Mayr NA, Lee HJ, et al.  Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy. AJR Am J Roentgenol. 2001;176:1525–1530
  24. Traill ZC, Talbot D, Golding S, et al.  Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin Radiol. 1999;54:448–451
  25. Hricak H, White S, Vigneron D, et al.  Carcinoma of the prostate gland (MR imaging with pelvic phased array coil versus integrated endorectal-pelvic phased-array coils). Radiology. 1994;193:703–709
  26. Huch Boni RA, Meyenberger C, Lundquist JP, et al.  Value of endorectal coil versus body coil MRI for diagnosis of recurrent pelvic malignancies. Abdom Imag. 1996;21:345–352
  27. Silverman JM, Krebs TL. MR imaging evaluation with transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol. 1997;168:379–385
  28. Bellin MF, Roy C, Kinkel K, et al.  Lymph node metastases (Safety and effectiveness of MR imaging with ultra small superparamagnetic iron oxide particles—Initial clinical experience). Radiology. 1998;207:799–808
  29. Kurhanewicz J, Vigneron DB, Males RG, et al.  The prostate (MR imaging and spectroscopy. Present and future). Radiol Clin North Am. 2000;38:115–138
  30. Kurhanewicz J, Vigneron DB, Hricak H, et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology. 1996;198:795–805
  31. Males RG, Vigneron DB, Star-Lack J, et al.  Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med. 2000;43:17–22
  32. Costello LC, Franklin RB. Citrate metabolism of normal and malignant prostate epithelial cells. Urology. 1997;50:3–12
  33. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999;12:413–439
  34. Scheidler J, Hricak H, Vigneron DB, et al.  Prostate cancer (localization with three-dimensional proton MR spectroscopic imaging—Clinicopathologic study). Radiology. 1999;213:473–480
  35. Wefer AE, Hricak H, Vigneron DB, et al.  Sextant localization of prostate cancer (Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology). J Urol. 2000;164:400–404
  36. Yu KK, Scheidler J, Hricak H, et al.  Prostate cancer (Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging). Radiology. 1999;213:481–488
  37. Zakian KL, Dyke J, Kurhanewicz J, et al.  Tracking metabolic response to neo-adjuvant chemotherapy in prostate cancer by proton magnetic resonance spectroscopic imaging. Proc Int Soc Magn Reson Med. 2000;1894; (abstr)
  38. Nudell DM, Wefer AE, Hricak H, et al.  Imaging for recurrent prostate cancer. Radiol Clin North Am. 2000;38:213–229
  39. Kalbhen CL, Hricak H, Shinohara K, et al.  Prostate carcinoma (MR imaging findings after cryosurgery). Radiology. 1996;198:807–811
  40. Kurhanewicz J, Vigneron DB, Hricak H, et al.  Prostate cancer (Metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging). Radiology. 1996;200:489–496
  41. Parivar F, Hricak H, Shinohara K, et al.  Detection of locally recurrent prostate cancer after cryosurgery (Evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy). Urology. 1996;48:594–599
  42. Chen M, Hricak H, Kalbhen CL, et al.  Hormonal ablation of prostatic cancer (Effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging). AJR Am J Roentgenol. 1996;166:1157–1163
  43. Mueller-Lisse UG, Swanson MG, Vigneron DB, et al.  Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med. 2001;46:49–57
  44. Mueller-Lisse UG, Vigneron DB, Hricak H, et al.  Localized prostate cancer: Effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: Clinicopathologic case-controlled study. Radiology. 2001;221:380–390
  45. Zakian KL, Sircar K, Kleinman S, et al.  Correlation of proton MR spectroscopic imaging with Gleason score based on step section radical prostatectomy. Proc Radiol Soc North Am. 2002;1525; (abstr)
  46. Algra PR, Bloem JL, Tissing H, et al.  Detection of vertebral metastases (comparison between MR imaging and bone scintigraphy). Radiographics. 1991;11:219–232
  47. Terris MK, Klonecke AS, McDougall IR, et al.  Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med. 1991;32:1713–1717
  48. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30:232–242
  49. Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552–558
  50. Kahn D, Wlliams RD, Manyak MJ, et al.  111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol. 1998;159:2041–2046
  51. Kahn D, Williams RD, Seldin DW, et al.  Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol. 1994;152:1490–1495
  52. Smith-Jones PM, Vallabhajosula S, Navarro V, et al.  Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen (Preclinical studies in nude mice bearing LNCaP human prostate tumor). J Nucl Med. 2003;44:610–617
  53. Jager PL, Vaalburg W, Pruim J, et al.  Radiolabeled amino acids (Basic aspects and clinical applications in oncology). J Nucl Med. 2001;42:432–445
  54. Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy (Correlation of US features with prostatic fossa biopsy findings). Radiology. 2001;219:432–439
  55. Kramer S, Gorich J, Gottfried HW, et al.  Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol. 1997;70:995–999
  56. Sella T, Schwartz LH, Swindle P, et al.  Endorectal coil MR in patients with PSA failure following radical prostatectomy. Radiological Society of North America, December 6, 2001, Chicago, IL. Radiology. 2002;225:351.E; (suppl, abstr)
  57. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy (Analysis of 136 scans of 100 patients). Prostate. 1998;37:261–269
  58. Sodee DB, Malguria N, Faulhaber P, et al.  Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology. 2000;56:988–993
  59. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002;94:987–996
  60. Seltzer MA, Barbaric Z, Belldegrun A, et al.  Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322–1328
  61. Zanzi I, Stark R. Detection of a non-Hodgkin’s lymphoma by capromab pendetide scintigraphy (ProstaScint) in a patient with prostate carcinoma. Urology. 2002;60:514
  62. Zucker RJ, Bradley YC. Indium-111 capromab pendetide (ProstaScint) uptake in a meningioma. Clin Nucl Med. 2001;26:568–569
  63. Scott DL, Halkar RK, Fischer A, et al.  False-positive 111 indium capromab pendetide scan due to benign myelolipoma. J Urol. 2001;165:910–911
  64. Khan A, Caride VJ. Indium-111 capromab pendetide (ProstaScint) uptake in neurofibromatosis. Urology. 2000;56:154
  65. Valliappan S, Joyce JM, Myers DT. Possible false-positive metastatic prostate cancer on an In-111 capromab pendetide scan as a result of a pelvic kidney. Clin Nucl Med. 1999;24:984–985
  66. Michaels EK, Blend M, Quintana JC. 111Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol. 1999;161:597–598
  67. Effert PJ, Bares R, Handt S, et al.  Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994–998
  68. Hofer C, Laubenbacher C, Block T, et al.  Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;36:31–35
  69. Liu IJ, Zafar MB, Lai YH, et al.  Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urol. 2001;57:108–111
  70. Turlakow A, Larson SM, Coakley F, et al.  Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose (Comparison of filtered back projection and iterative reconstruction with segmented attenuation correction). Q J Nucl Med. 2001;45:235–244
  71. DeGrado TR, Coleman RE, Wang S, et al.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography (Initial findings in prostate cancer). Cancer Res. 2001;61:110–117
  72. Kotzerke J, Volkmer BG, Neumaier B, et al.  Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380–1384
  73. Fricke E, Machtens S, Hofmann M, et al.  Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607–611
  74. Oyama N, Miller TR, Dehdashti F, et al.  11C-acetate PET imaging of prostate cancer (Detection of recurrent disease at PSA relapse). J Nucl Med. 2003;44:549–555
  75. Picchio M, Messa C, Landoni C, et al.  Value of[11C]choline-positron emission tomography for re-staging prostate cancer (A comparison with [18F]fluorodeoxyglucose-positron emission tomography). J Urol. 2003;169:1337–1340
  76. Hara T. 11C choline and 2-deoxy-2- [18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol. 2002;4:267–273
  77. Kato T, Tsukamoto E, Kuge Y, et al.  Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia (Comparison with prostate cancer). Eur J Nucl Med Mol Imaging. 2002;29:1492–1495
  78. Levesque PE, Nieh PT, Zinman LN, et al.  Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology. 1998;51:978–984
  79. Kahn D, Williams RD, Haseman MK, et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284–289
  80. Thomas CT, Bradshaw PT, Pollock BH, et al.  Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003;21:1715–1721
  81. Lee CT, Oesterling JE. Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am. 1997;24:389–394
  82. Cher ML, Bianco FJ, Lam JS, et al.  Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387–1391
  83. Palmer E, Henrikson K, McKusick K, et al.  Pain as an indicator of bone metastasis. Acta Radiol. 1988;29:445–449
  84. Turner JW, Hawes DR, Williams RD. Magnetic resonance imaging for detection of prostate cancer metastatic to bone. J Urol. 1993;149:1482–1484
  85. Schirrmeister H, Glatting G, Hetzel J, et al.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800–1804
  86. Savelli G, Maffioli L, Maccauro M, et al.  Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45:27–37
  87. Delpassand ES, Garcia JR, Bhadkamar V, et al.  Value of SPECT imaging of the thoracolumbar spine in cancer patients. Clin Nucl Med. 1995;20:1047–1051
  88. Even-Sapir E, Martin RH, Barnes DC, et al.  Role of SPECT indiffernentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology. 1993;187:193–198
  89. Imbriaco M, Larson SM, Yeung HW, et al.  A new parameter for measuring metastatic bone involvement by prostate cancer (The bone scan index). Clin Cancer Res. 1998;4:1765–1772
  90. Sabbatini P, Larson SM, Kremer A, et al.  Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17:948–957
  91. Noguchi M, Kikuchi H, Ishibashi M, et al.  Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer. Br J Cancer. 2003;88:195–201
  92. Van der Wall H. The evaluation of malignancy (Metastatic bone disease). In:  Murray IPC,  Ell PJ editor. ed 2. Nuclear Medicine in Clinical Diagnosis and Treatment. vol 2:Edinburgh, Scotland: Churchill Livingstone; 1998;p. 1169–1184
  93. Pomeranz WJ, Pretorius HT, Ramsingh PS. Bone scinitgraphy and Multimodality imaging in bone neoplasia (Strategies for imaging in the new health climate). Semin Nucl Med. 1994;24:188–207
  94. Yeung H, Schoder H, Larson S. Utility of PET/CT for assessing equivocal PET lesions in oncology—Initial experience. J Nucl Med. 2002;43:32P; (abstr)
  95. Morris MJ, Akhurst T, Osman I, et al.  Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913–918
  96. Nunez R, Macapinlac HA, Yeung HW, et al.  Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46–55
  97. Pollen JJ, Witztum KS, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol. 1984;142:773–776
  98. Schneider JA, Divgi CR, Scott AM, et al.  Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med. 1994;35:1748–1752

PII: S0093-7754(03)00359-2

doi: 10.1016/S0093-7754(03)00359-2

Seminars in Oncology
Volume 30, Issue 5 , Pages 616-634 , October 2003

Article Tools

* Image Usage & Resolution